Spinal Muscular Atrophy (SMA): Causes, Types, Symptoms, and Treatments

Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by homozygous loss-of-function mutations in SMN1 (survival motor neuron 1) on chromosome 5q13. This leads to deficiency of SMN protein—essential for motor neuron survival.

Genetics

  • SMN1 deletion/mutation: Accounts for >95% of cases (exon 7 deletion most common)
  • SMN2 copy number modifies severity: SMN2 produces only ~10–15% functional SMN; more copies generally mean milder phenotype
  • Carrier frequency: ~1/40–1/60 across ethnicities
  • Inheritance: Autosomal recessive (25% recurrence risk if both parents are carriers)

Classification by Onset and Maximum Motor Function (Natural History)

TypeOnsetMax Motor MilestoneLife Expectancy (Untreated)
Type 0 (Prenatal)FetalNone; arthrogryposisPerinatal
Type 1 (Werdnig-Hoffmann)<6 monthsNever sits independently<2 years (respiratory failure)
Type 2 (Dubowitz)6–18 monthsSits; never walks independentlyAdulthood (with respiratory support)
Type 3 (Kugelberg-Welander)>18 monthsWalks; may lose ability laterNormal
Type 4 (Adult-onset)AdulthoodWalks; slow progressionNormal

Clinical Features

  • Symmetric proximal > distal weakness
  • Hypotonia, areflexia, fasciculations (especially tongue)
  • Bell-shaped chest, paradoxical breathing (Type 1)
  • Scoliosis, hip dislocation, contractures
  • Bulbar weakness: swallowing and speech difficulties
  • Intact cognition and sensation

Disease-Modifying Therapies (Transformative Since 2016)

  • Nusinersen (Spinraza®): Antisense oligonucleotide splicing modifier → increases SMN2 exon 7 inclusion; intrathecal every 4 months after loading; all types
  • Risdiplam (Evrysdi®): Oral daily splicing modifier; all ages and types; home administration
  • Onasemnogene abeparvovec (Zolgensma®): AAV9-SMN1 gene replacement; single IV dose; <2 years (weight-based); highest impact in pre-symptomatic/Type 1

Supportive Care (Essential Alongside DMTs)

  • Respiratory: NIV, cough assist, secretion clearance, vaccination
  • Nutritional: G-tube if dysphagia; reflux management
  • Orthopedic: Scoliosis bracing/surgery; contracture prevention
  • Rehabilitation: PT/OT/Aqua therapy; maintain function, prevent disuse atrophy
  • Multidisciplinary clinic: Neuromuscular, pulmonology, orthopedics, GI, genetics, palliative care

Newborn Screening

  • Now universal in the US (all 50 states) and many countries
  • Enables pre-symptomatic treatment—dramatically alters disease trajectory

Prognosis

With early treatment (especially pre-symptomatic), motor milestones are achieved, survival is normalized, and ventilation is avoided in many patients. Long-term durability and combination therapies remain under active study.

Bones, Joints & Muscles - Related Articles